BRIEF published on 08/12/2024 at 13:05, 1 year 8 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 8 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 9 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 9 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 10 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 10 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 10 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 10 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 05/04/2026 at 13:00, 7 minutes ago Eagle Plains and Xcite Expand Beaver River Uranium Project
Published on 05/04/2026 at 13:00, 7 minutes ago Mako Mining Intersects 26.98 g/t Au over 6.8 m Estimated True Width at Las Conchitas, Extending an Area Fully Permitted for Mining to Over 450 m of Strike
Published on 05/04/2026 at 10:30, 2 hours 37 minutes ago Storm Exploration Plans Drill Program to Test VMS Target at Gold Standard
Published on 05/04/2026 at 01:40, 11 hours 27 minutes ago New Head of Corporate Affairs and Sustainability
Published on 05/02/2026 at 21:00, 1 day 16 hours ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/04/2026 at 12:40, 27 minutes ago EQS-Adhoc: SOWITEC group GmbH and the Joint Representative enter into a deferral agreement regarding a partial repayment of the bond 2018/2026
Published on 05/04/2026 at 12:31, 35 minutes ago EQS-Adhoc: Basler AG reports preliminary financial results for the first quarter of 2026: Very strong start to the year; company raises forecast for 2026
Published on 05/04/2026 at 12:00, 1 hour 7 minutes ago Aroundtown SA: Release of a capital market information
Published on 05/04/2026 at 11:39, 1 hour 28 minutes ago swissnet Group sichert sich bedeutenden Hospitality-Netzwerkinfrastrukturauftrag in Dubai
Published on 05/04/2026 at 11:16, 1 hour 50 minutes ago EQS-Adhoc: Basler AG reports preliminary financial results for the first quarter of 2026: Very strong start to the year; company raises forecast for 2026
Published on 05/04/2026 at 09:51, 3 hours 15 minutes ago GUILLEMOT CORPORATION: Weekly report share buyback From April 27th 2026 to May 1st 2026
Published on 05/04/2026 at 08:45, 4 hours 22 minutes ago Air Liquide divests its biogas production activities in four countries
Published on 04/30/2026 at 20:00, 3 days 17 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 3 days 17 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 3 days 18 hours ago Capital increase through exercise of subscription rights
